Nevro Corp

NYSE:NVRO  
85.86
-1.01 (-1.16%)
Regulatory, Earnings Announcements

Nevro Announces Three Important Clinical Data Publications For Treating Painful Diabetic Neuropathy With 10 Khz Therapy

Published: 11/29/2021 16:21 GMT
Nevro Corp (NVRO) - Nevro Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy With 10 Khz Therapy.
Nevro Corp - Senza-pdn 12-month Data Randomized Controlled Trial Show Hfx for Pdn Significantly, Durably Reduces Painful Diabetic Neuropathy Symptoms.
Nevro Corp - in Senza-pdn 12-month Trial, Safety Was Consistent With Published Reports of Adverse Event Rates in Traditional Scs Trials.
Revenue is expected to be $96.58 Million
Adjusted EPS is expected to be -$0.87

Next Quarter Revenue Guidance is expected to be $93.1 Million
Next Quarter EPS Guidance is expected to be -$0.80

More details on our Analysts Page.